Diggs et al. treated iCCA mice with a combination of anti-CD40 and anti-PD-1, resulting in a much lower tumor burden as well as enhanced numbers and activation of CD4+ and CD8+ T cells, NK cells, and myeloid cells in the tumor [45]. The gene discussed is CD8A; the disease is neoplasm.